Nutriband (NASDAQ: NTRB), a company primarily engaged in the development of transdermal pharmaceutical products, announced that its CEO, Gareth Sheridan, is featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the opioid crisis in the United States. The documentary focuses on the ongoing public health emergency and potential solutions. Sheridan discusses pharmaceutical innovation and technologies, including Nutriband's AVERSA(TM) abuse-deterrent platform, which is designed to reduce the risk of abuse, misuse, diversion, and accidental exposure associated with high-risk medications while preserving access for patients with legitimate medical needs.
The opioid crisis remains a critical issue in the U.S., with overdose deaths involving prescription opioids and illicit opioids continuing to rise. According to the Centers for Disease Control and Prevention, opioids were involved in over 80,000 deaths in 2021. In this context, Nutriband's AVERSA technology represents a potential advancement in harm reduction. The platform can be incorporated into any transdermal patch to deter abuse. Nutriband's lead product under development is an abuse-deterrent fentanyl patch that incorporates AVERSA technology. If approved, this product could provide a safer option for patients requiring powerful pain relief while reducing the risk of diversion and accidental exposure, particularly for children and pets.
For investors, Nutriband's inclusion in the documentary may raise its profile and highlight the potential of its pipeline. The company's focus on abuse-deterrent technologies aligns with broader industry trends toward safer drug delivery systems. As the opioid crisis persists, solutions like AVERSA could attract regulatory support and market demand. However, the company remains in the development stage, and the path to commercialization involves clinical trials and regulatory approvals. The documentary, by bringing attention to these innovations, may also influence public perception and policy discussions. More information about Nutriband's news and updates is available in its newsroom at https://ibn.fm/NTRB.
The announcement was distributed via InvestorWire, a specialized communications platform that provides wire-grade press release syndication. InvestorWire is part of IBN's Dynamic Brand Portfolio, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by InvestorWire, visit https://www.InvestorWire.com/Disclaimer.
